Woodline Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Woodline Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80.7M	Buy	243,883 +242,124	+13,765%	+$82.4M	0.31%	63
2025 Q4	$699K	Sell	1,759 -90,032	-98%	-$39.8M	﹤0.01%	870
2025 Q3	$41.9M	Sell	91,791 -531,324	-85%	-$216M	0.2%	142
2025 Q2	$203M	Buy	623,115 +466,651	+298%	+$129M	1.07%	6
2025 Q1	$42.2M	Buy	+156,464	New	+$40.2M	0.27%	111
2023 Q1	–	Sell	-95,068	Closed	-$22.6M	–	626
2022 Q4	$22.6M	Buy	+95,068	New	+$20.3M	0.3%	89

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners's ALNY Position: Q1 2026 in Review

Woodline Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 13,765% in Q1 2026, buying an estimated $82.4M and bringing the position to 243,883 shares worth $80.7M. The position accounts for 0.31% of the portfolio, ranked #63.

Woodline Partners first reported a position in ALNY in Q4 2022 and has held it in 6 quarters since. The position peaked at $203M in Q2 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Woodline Partners held 243,883 shares of Alnylam Pharmaceuticals worth $80.7M as of Q1 2026.
Woodline Partners bought 242,124 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $82.4M.
Alnylam Pharmaceuticals made up 0.31% of Woodline Partners's portfolio in Q1 2026, its #63 holding.
Woodline Partners first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
Woodline Partners's Alnylam Pharmaceuticals position peaked at $203M in Q2 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.